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AbstrACt 
Objective Bisphosphonate-related osteonecrosis 
of the jaw (BRONJ) is a rare but serious side effect 
of bisphosphonates (BPs). Since this disease has no 
independent code in either of the diseases’ or in the 
medical procedures’ classifications, it is hard to estimate 
how many BP patients are affected.
Design A retrospective observational epidemiological 
registry-based study was carried out, using the data of the 
national service of Hungary on the incidence of BRONJ and 
related factors.
setting A data analysis was performed, which is relevant 
for the whole Hungarian population from 2010 to 2014. 
The socioeconomic and medication data of 236 207 BP 
patients were analysed, and a method was worked out to 
define BRONJ patients from the Hungarian BP population.
Primary and secondary outcome measures The 
incidences of BRONJ were analysed according to genders 
and the types of the BP drugs administered. The marginal 
interdependence between the types of BP drugs, modes of 
administration and main indication was calculated.
results 340 BP patients (0.1%) developed BRONJ. The 
incidence of BRONJ in Hungary in the malignant indication 
of BPs is 0.9%, and 0.1% in the non-malignant indication, 
and the OR to develop BRONJ was OR=9.7 (95% CI 7.8 
to 12.1) between them. Although more women developed 
BRONJ, the proportion of men was significantly higher 
than that of women. Steroids increase the risk of jaw 
osteonecrosis, and differences were also found between 
the BP drugs.
Conclusions Oncology indicated, intravenously 
administered and steroid comedicated BP therapies pose a 
high risk of developing BRONJ in the Hungarian population.
IntrODuCtIOn
Bisphosphonate-related osteonecrosis of the 
jaw (BRONJ) was first mentioned in the liter-
ature by Marx in 2003 and it was defined as a 
new disease by Ruggiero in 2004.1 2 The first 
guideline of the American Association of Oral 
and Maxillofacial Surgeons on BRONJ was 
published in 2007.3 This position paper was 
updated in 2009 and 2014.4 5 As per defini-
tion, BRONJ is present when there is denuded 
bone in the maxillofacial region which 
persists for >8 weeks from the diagnosis and 
the patients have been treated with bisphos-
phonate (BP) despite no history of irradi-
ation to the head and neck region.4 Since 
2014 the disease group has been called medi-
cation-related ONJ (MRONJ), considering 
the antiresorptive and antiangiogenic drugs 
which potentially cause the disease.5 
BRONJ is a characteristic side effect of 
BPs.6 The factors affecting the development 
of the necrosis are numerous. However, 
female gender and age seem to be risk factors 
by themselves.3 7 Potential risk factors include 
medical, local, demographical, genetic and 
usual risk factors (eg, tobacco use, obesity), as 
well as comorbidities (renal failure, anaemia, 
diabetes). Besides, it also poses a risk what 
kind of disease (malignant or non-malignant) 
is treated with BP. The potential, namely the 
drug type, the mode and the length of the 
administration of BP and the types of co-med-
ications can also present a risk.4 8–12 Among 
comedications, corticosteroids, immunosup-
pressants, antioestrogens and chemotherapy 
can increase the risk of the development of 
BRONJ.13–18
strengths and limitations of this study
 ► Bisphosphonate-related osteonecrosis of the 
jaw  (BRONJ) is a rare but very serious side effect 
of bisphosphonates (BPs), but it is hard to estimate 
how many BP patients are affected.
 ► A research method is developed to find BRONJ pa-
tients in the BP population.
 ► Since there is no independent codes of disease or 
medical procedures for this disease, a selection bias 
can occur, which is the limitation of the study. The 
applied screening method narrows the number of 
potential BRONJ patients.
 ► The study was not registered in any databases of 
clinical studies.
 ► More studies are needed with a logistic regression 
model to find the interdependence of the analysed 
factors.
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Aims of the study
BRONJ has no independent code in the International 
Classification of Diseases (ICD) and related health prob-
lems, which makes it difficult to identify the patients who 
develop BRONJ (BRONJ patients). The aim of this work 
was to work out a method with which BRONJ patients 
can be chosen out of the patients treated with BPs (BP 
patients) whether they have a malignant or a non-malig-
nant disease and to analyse the incidence and the risk 
factors of this side effect in the Hungarian population. It 
is hypothesised that there is a higher risk for developing 
BRONJ of the administration of BPs used in the malig-
nant than in the non-malignant indication.
Ethics approval
The patients’ healthcare data (prescriptions’ data, ICD 
codes and codes of medical procedures) for the analyses 
were available from the National Healthcare Services 
Center’s (NHSC) database through a research contract. 
The NHSC collects and handles the data of the National 
Health Insurance Fund (NHIF) of Hungary as a basic 
task and, therefore no ethics approval was needed for this 
study. The patients’ personal data were converted to iden-
tification number (IDs) and the aggregated medical data 
were used for the evaluation, which can be considered 
blinding. None of the patients can be identified in any 
ways for the members of the research group.
MEthOD
study design and patients
A retrospective observational epidemiological regis-
try-based study was carried out. The incidences of BRONJ 
were analysed according to genders, and the types of the 
BP drugs. The marginal interdependence between the 
types of BP drugs, modes of administration and main 
indication was calculated.
Patient and public involvement
Patients and public were not involved in the design and 
conduct of the study.
Database and data collection
To obtain enough data for the analysis of this rare side 
effect, the study team decided to analyse the health-
care data of the Hungarian population. In Hungary, the 
NHIF is the only organisation to reimburse healthcare-re-
lated expenditures, including medicines and healthcare 
institutions, which gives a nationwide relevance for the 
analysis. To avoid the disturbing effect of the other drugs 
causing ONJ, the available data were collected from 
1 January 2010 to 31 December 2014. Since the period of 
the screening covers the era of the BRONJ, this definition 
has been used throughout the manuscript. The selected 
time frame ensured that the earliest available data were 
analysed from the study start date, and the end date 
assures that only the effect of the BP drug group was anal-
ysed without the effect of other drugs which can cause 
MRONJ. The data were handled by professional experts 
of data handling from the NHSC, and they are coauthors 
of this paper (TB-L and ZP). The database of the NHSC 
is a validated database with limited access for users. This 
database is the basis of the Hungarian reimbursement 
system. Since the data analysed were extracted from a 
validated database, a group of randomly selected patients 
were chosen for the validation based on their coded 
personal healthcare data and the prescribed medicines.
First, the prescription data of the BP type medicines 
under Anatomical Therapeutic Chemical (ATC Classifica-
tion System) codes were collected as follows: M05BA—bi-
sphosphonates and M05BB—bisphosphonate combinations. 
The prescription data contain the ICD code, which stands 
for the main indication of the use of the medication. 
This screen resulted in the BP population of Hungary. 
BRONJ patients were selected from the BP population 
using the NHIF inpatient care database. The selected 
ICD and International Classification of Procedures in 
Medicine (ICPM and related health problems) codes are 
shown in figure 1. In this study, the BP patients selected 
according to both ICD and ICPM codes were defined as 
BRONJ patients. Irradiation to the head and neck region 
was considered an exclusion criterion. The ICPM codes 
of the irradiations were defined from the inpatient and 
outpatient care ICPM database of Hungary. NHIF refers 
to the ICPM codes as a basis of reimbursement. The 
parameters in the BRONJ patients’ group were analysed 
until the first ICD or ICPM code in connection with 
BRONJ appeared. The no BRONJ group consists of the 
patients chosen from the database according to the ATC 
code of the prescribed medicine and have not developed 
BRONJ during the study time period. In this group, these 
parameters were taken into consideration for the whole 
time period of the study.
The effect of BPs was analysed according to drug types 
(different types of BP drugs: alendronate, clodronate, 
ibandronate, pamidronate, risedronate and zoledronic 
acid) and main indications. Malignant (M) and non-ma-
lignant (NM) groups of indications were separated on 
the basis of the name, package and reimbursement tech-
nique of the dispensed BP drug.19 The BP medicines 
with an indication of advanced malignancies involving 
bone (eg, the skeletal events of breast cancer, prostate 
cancer or multiple myeloma or tumour-induced hyper-
calcaemia) were administered to M patients, and NM 
patients were treated with BPs for postmenopausal, male 
or glucocorticoid-induced osteoporosis or Paget’s disease 
of the bone. The patients included were grouped into 
Oral and Intravenous groups according to the mode of 
administration of the BP. In the Oral group, patients took 
their BP medicines orally. In the Intravenous group, BP 
drugs were administered to the patients intravenously or 
both intravenously and orally because the risk of BRONJ 
with intravenous BPs can be 100–1000 times higher than 
the risk with oral BPs.5 In the case of patients taking oral 
BPs, a 182-day time shift was required between the first BP 
dispensing and the onset of the disease.2 3 No time shift 
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was required in the case of intravenous BPs because these 
medicines might increase the risk of BRONJ right after 
the first administration.
In this study, therapy switch was defined when another 
BP drug type and/or the same drug in another route was 
administered to a predefined patient. The doses of the 
different drug types were made comparable by using a 
relative total dose (RTD). Defined daily dose of drugs were 
used to calculate days of therapy (DOTs) of the medica-
tions. Dividing the DOT amounts of the dispensed BP 
drugs for every patient with the days spent at risk in the 
study time period gives the amount of the RTD. The days 
spent at risk means the study time period for non-necrosis 
patients. For necrosis patients, it means the days spent 
Figure 1 Method of the definition of the Hungarian BP and BRONJ population. This figure represents the method which has 
been worked out to identify BRONJ patients from the Hungarian BP population. The BP users were screened according to the 
ATC code of the prescribed medicine from 2010 to 2014. After the exclusion of the patients who were irradiated in the head and 
neck region, a dual screen of the BRONJ patients was applied. According to the definition of this study, the BRONJ patients 
group consists of those patients whose data contain both the ICD and the ICPM codes regarding BRONJ. ATC, Anatomical 
Therapeutic Chemical; BP, bisphosphonate; BRONJ, bisphosphonate-related osteonecrosis of the jaw; ICD, International 
Classification of Diseases; ICPM, International Classification of Procedures in Medicine.
Table 1 Age and gender characteristics of the study population 
Number of patients Age
BRONJ (%) No BRONJ (%) Total BRONJ (±SD) No BRONJ (±SD) Total (±SD)
Male patients 94 (0.3) 31 802 (99.7) 31 896 66.2 (61.0–71.5) 67.4 (61.2–73.6) 67.4 (61.2–73.6)
Female patients 246 (0.1) 204 009 (99.9) 204 255 65.0 (60.0–70.0) 68.7 (63.7–73.7) 68.7 (63.7–73.7)
Total 340 (0.1) 235 811 (99.9) 236 207 65.4 (60.3–70.4) 68.5 (63.3–73.7) 68.5 (63.3–73.7)
BRONJ, bisphosphonate-related osteonecrosis of the jaw.
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between the beginning of the study and the first occur-
rence of an ICD or ICPM code related to the BRONJ.
The BP patients were selected from the study popula-
tion to whom steroids (ATC group H02) were dispensed 
any number of times to analyse the effect of corticosteroid 
comedication. The risk increasing effect of the RTD of the 
BPs and the BP drug types were analysed in this group.
statistical analysis
IBM SPSS Statistics V.20 programme was applied for the 
statistical analyses. Evaluation was performed by descriptive 
analysis, the kind of distribution of the data was checked 
by Kolgomorov-Smirnov test. For the comparisons of the 
proportions of the BRONJ caused by the different drug 
compounds, administration modes and main indications, 
Student’s t-test was applied. Marginal interdependence 
between the variables (genders, drug compounds and so 
on) was calculated by counting marginal ORs and 95% CIs. 
Mood’s median test was used when the non-normally distrib-
uted data (RTDs of the drugs) were compared between 
patients’ groups. The χ2 test was selected to analyse the 
Table 2 Comparison of the main indications with administration routes and therapy switch of the bisphosphonates 
Gender and main indication of 
bisphosphonates* BRONJ  (%) No BRONJ (%) OR (95% CI) P value
Male 
  Malignant 68 (0.9) 7955 (99.1)
7.3 (4.7 to 11.4) <0.0001  Non-malignant 28 (0.1) 24 046 (99.9)
Female 
  Malignant 65 (1.0) 6465 (99.0) 10.9 (8.2 to 14.5) <0.0001
  Non-malignant 183 (0.1) 198 220 (99.9)
Main indication and route of adminisrtation of bisphoshponates 
Malignant and non-malignant disease 
  Intravenous 4 (0.7) 604 (99.3) 3.2 (0.2 to 59.8) 0.43
  Oral 0 (0.0) 215 (100.0)
  Total 4 (0.5) 819 (99.5)
Malignant disease 
  Intravenous 111 (1.2) 9409 (98.8) 2.8 (1.7 to 4.5) 0.0001
  Oral 18 (0.4) 4210 (99.6)
  Total 129 (0.9) 13 619 (99.1)
Non-malignant disease 
  Intravenous 67 (0.1) 51 158 (99.9) 1.7 (1.3 to 2.2) 0.0004
  Oral 140 (0.1) 170 271 (99.9)
  Total 207 (0.1) 221 429 (99.9)
Total 
  Intravenous 182 (0.3) 61 171 (99.7) 3.3 (2.7 to 4.1) <0.0001
  Oral 158 (0.1) 174 696 (99.9)
  Total 340 (0.1) 235 864 (99.9)
Therapy switch in the groups of oral and intravenous administrations 
Oral bisphosphonates 
  1 type 146 (0.1) 151 390 (99.9) 1.9 (1.0 to 3.4) 0.04
  <1 type 12 (0.1) 23 285 (99.9)
  Total 158 (0.1) 174 675 (99.9)
Intravenous bisphosphonates 
  1 type 167 (0.3) 58 102 (99.7) 0.9 (0.5 to 1.5) 0.69
  <1 type 15 (0.5) 3069 (99.5)
  Total 182 (0.3) 61 171 (99.7)
Bold values are highlighting results. 
*In malignant and non-malignant groups, patients taking bisphosphonates in both indications are present.
BRONJ, bisphosphonate-related osteonecrosis of the jaw.
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difference between categorical variables. The level of signif-
icance was p≤0.05.
rEsults
Using the method developed for this study, the Hungarian 
BP population in the study time period amounted to 
236 207 patients. As a result of the two screening criteria, 
the BRONJ patients’ number came up to 340 (0.1%). The 
age and gender characteristics of the study population are 
presented in table 1, while the comparison of the basic 
indications and the routes of administration of BPs are 
presented in table 2. Our results show significantly more 
BRONJ cases in male than in female BP patients, p<0.001.
There was a significant difference between the BRONJ 
and the No BRONJ groups from the point of view of age, 
p<0.001. In the BRONJ group, the proportion of female 
patients (F/M: 72.4%/27.7%) was significantly lower 
than in the whole study population (F/M: 86.5%/13.5%), 
p<0.001. The male patients developed BRONJ with a 2.5 
times higher odds (95% CI 1.9 to 3.1, p<0.001) than female 
patients. The proportion of oncology patients was higher 
in male than in female patients (F/M: 3.2%/25.2%). 
With a multinomial χ2 test, this difference was significant, 
p<0.001. 72.3% of male and 26.4% of female BRONJ 
patients used their BPs in malignant indications. A multi-
nomial χ2 probe showed that the difference was also 
significant between males and females, p<0.001.
The new BRONJ cases in the 5-year study time period 
numbered 133 in the M indication of BPs, and 211 in 
the NM group. These data also include the patients with 
combined indications of BPs. On the basis of these results, 
the incidences were 0.9% and 0.1%, respectively. The 
BRONJ patients’ proportion was significantly higher in 
the oncology BP group than that in the study population 
(p<0.001), and also than that of the non-malignant indi-
cation (OR=9.7, 95% CI 7.8 to 10.1, p<0001). In the Intra-
venous BP group, the proportion of BRONJ patients was 
significantly higher than that in the whole study popu-
lation (p<0.001). In the oral BP group of patients who 
took one drug type, the BRONJ patients’ proportion was 
significantly higher than that in the total oral BP popu-
lation (p=0.04). Relatively more BRONJ patients treated 
with more types of BP drugs were found in the Intrave-
nous BP patients’ group, but in the Oral pantients’ group 
the odds of patients who took one type of BP was higher 
than that of patients who were administered more BP 
drug types. These results are presented in table 2.
Table 3 presents the proportion of BRONJ patients in 
drug types with administration modes. According to the 
results of the multinomial χ2 test, the proportion of BRONJ 
patients was significantly higher in the clodronate, oral 
ibandronate, pamidronate and zoledronic acid groups 
than those in the study population. In the alendronateand 
risedronate groups, the proportion of BRONJ patients was 
significantly lower than in the total population.
The mean RTDs of the dispensed BPs are presented in 
table 4 according to drug types.
The difference in the proportion of BRONJ cases was 
defined between each pair of drug types. Table 5 gives the 
p values and ORs. This shows whether a drug compound 
has a stronger effect on the development of BRONJ than 
another.
Glucocorticoid comedication
In the BP patients’ group treated with glucocorticoids 
(steroid BP group; n=44 784), the proportion of BRONJ (80 
patients, 0.2%) was significantly higher than in the steroid 
non-taker BP group (n=191 423, BRONJ: 260 patients, 
0.1%) (p=0.013), OR=1.3 (95% CI 1.0 to 1.7, p=0.03). In 
Table 3 Cumulative effect of bisphosphonate drug types and routes of administration in the study population 
Drug and 
administration route BRONJ (%) No BRONJ (%) Total P value Necroses 
Clodronate oral 23 (6.8) 4588 (1.9) 4 611 <0.001 More necroses
Clodronate 
intravenous
0 (0.0) 65 (0.0) 65 0.75 Not significant
Ibandronate oral 29 (8.5) 11 408 (4.8) 11 437 0.003 More necroses
Ibandronate 
intravenous
44 (12.9) 35 850 (15.2) 35 894 0.31 Not significant
Pamidronate 
intravenous
11 (3.2) 1223 (0.5) 1234 <0.001 More necroses
Alendronate oral 133 (39.1) 142 075 (60.2) 142 208 <0.001 Fewer necroses
Risedronate oral 46 (13.5) 66 451 (28.2) 66 497 <0.001 Fewer necroses
Zoledronic acid 
intravenous
142 (41.8) 27 117 (11.5) 27 259 <0.001 More necroses
Total 340 (100.0) 235 867 (100.0) 236 207 NA Basis of comparison
Whether the given drug compound and administration route result in more or fewer necroses than it was found in the whole 
study population.
BRONJ, bisphosphonate-related osteonecrosis of the jaw.
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the group of steroid BP patients, there were two BRONJ 
cases among the patients treated with BPs both in M and in 
NM indications (n=283, BRONJ 0.71%, p=0.04), and in M 
indications there were 37 BRONJ cases out of 2839 patients 
(1.3%, p<0.001), significantly higher than those of the total 
steroid BP population. In the NM group, 41 BRONJ cases 
out of 41 662 steroid BP patients occurred (0.1%), signifi-
cantly fewer than in the total steroid BP group (p=0.0016). 
There is a 12.3 OR (95% CI 8.0 to 19.0, p<0001) between 
the M and NM steroid patients’ groups to develop BRONJ. 
There is no significant difference between the group of 
both indications and the M BP groups (p=0.39), but the 
result of the M BP group is significantly higher than that of 
the NM indication group (p<0.001).
Carrying out a Mood’s median test, the median RTD of 
BPs in the patients who took steroids with BPs (median 
RTD: 0.481 [0.2–0.9]) does not differ from that of those 
patients who did not take steroids (median RTD: 0.473 
[0.2–1.0]). Steroid BRONJ patients’ (n=80, median RTD of 
BPs: 0.771 [0.5–1.1]) median total RTD of BPs was signifi-
cantly higher than that of the No BRONJ steroid patients 
(n=44 704, the median RTD of BPs was 0.481 [0.2–0.9]) 
(p<0.001). The RTD of BP is higher in the steroid BRONJ 
group in the case of oral clodronate, parenteral ibandro-
nate, pamidronate and zoledronic acid. This difference is 
only significant in the zoledronic acid BP group, p<0.001. 
The RTD of BP is lower in the steroid BP group of patients 
in the oral ibandronate, alendronate and risedronate BP 
groups, in which only risendronate is significant: p=0.001.
DIsCussIOn
BRONJ has not been studied in the Hungarian popula-
tion yet. The higher number of BRONJ in male patients 
is attributed to the fact that there is a higher proportion 
of male than female oncology patients in the Hungarian 
BP population. The number of female BRONJ patients 
was higher because women make up more of the total BP 
population (postmenopausal osteoporosis). According 
to the results, the proportion of male BRONJ patients 
was higher even in the NM indication of BPs than that 
of female BRONJ patients. The underlying cause was 
presumably the increasing use of intravenous BPs 
because of non-adherence and the presence of other (eg, 
local) risk factors. Since the database of the Hungarian 
NHIF provides the medical and the main demographical 
data of the patients, but the local, genetic and usual risk 
factors are not included, these factors were not accessible 
for the analyses.
The results of the studies on the incidence of 
BRONJ cover a wide range. The results of this study 
are comparable to the international results of malig-
nant (0.9%/0.8%–11%) and also non-malignant indi-
cations of BPs (0.1%/0.001%–0.7%).20–38 The number 
of patients with osteoporosis in Hungary is increasing. 
These patients’ adherence is very low and a relatively high 
number of patients receive no adequate treatment.39 The 
latter results in the under treatment of these patients, but 
side effects or medical combinations which increase the 
risks of side effects might occur in the long term.
Switching therapy (using more than one type of BP drug 
or using the same drug in another administration route) 
in a group of a single drug type usually increases the risk 
of side effects. From the references, it can be concluded 
that in the case of intravenous BPs, the BP type and the 
length of therapy have a stronger effect than the switch 
itself.31 33 In this study population, more BRONJ occured 
in the patients’ group treated with one type of oral BPs 
than in the switched group, and there were more BRONJ 
cases in the switched intravenous BP group than in the 
non-switched group. Oral BPs are mainly used in non-ma-
lignant indications, and the length of therapy might 
have a stronger effect on the risk of BRONJ than the 
switching therapy. In oncology, clodronate might be used 
to increase the effect of other intravenous BPs, or the less 
effective BP might be changed for a more effective one to 
Table 4 Mean relative total doses of the drugs with 
administration routes in the BRONJ and No BRONJ patients’ 
groups
Relative total 
doses Mean SD SE mean P value
Clodronate oral 
  BRONJ 0.055 0.32 0.02 0.007
  No BRONJ 0.008 0.48 0.00
Clodronate intravenous 
  BRONJ 0.000 0.00 0.00 0.80
  No BRONJ 0.000 0.00 0.00
Ibandronate oral 
  BRONJ 0.137 1.34 0.07 0.15
  No BRONJ 0.033 0.95 0.00
 Ibandronate intravenous 
  BRONJ 0.089 0.39 0.02 0.69
  No BRONJ 0.080 0.45 0.00
 Pamidronate intravenous 
  BRONJ 0.026 0.17 0.01 0.009
  No BRONJ 0.002 0.03 0.00
Alendronate oral 
  BRONJ 0.474 1.17 0.06 0.79
  No BRONJ 0.434 2.80 0.01
Risedronate oral 
  BRONJ 0.106 0.48 0.03 0.46
  No BRONJ 0.171 1.62 0.00
Zoledronate intravenous 
  BRONJ 0.338 0.83 0.05 <0.001
  No BRONJ 0.065 0.65 0.00
Bold values are statistically significant.
 The mean relative total doses of the drugs in the BRONJ and No 
BRONJ patients’ groups and the differences that were found.
BRONJ, bisphosphonate-related osteonecrosis of the jaw.
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improve patient status in the short term. Non-aminoBP 
clodronate has no proven risk-increasing effect, but the 
cumulative effect of BPs cannot be excluded.40 41
In contrast to previous studies, our study illustrates that 
there were more BRONJ patients in the group of alendro-
nate and ibandronate patients during the study period 
in Hungary. BRONJ in the weekly administered alendro-
nate patients is 0.01%–0.04%.23 This ratio was 0.09% in 
this study, which might be the result of the status of the 
Hungarian patients with osteoporosis: the number on 
alendronate is very high, but adherence is inadequate.42 
In the references, 0.05%–0.07% of the long-term iban-
dronate users develop BRONJ, which is lower than our 
result of 0.12% (intravenous ibandronate) and 0.25% 
(oral ibandronate) in the case of the non-malignant iban-
dronate users.43 44 A lower incidence of BRONJ (0.89%) 
was found in the present study among the patients who 
were administered pamidronate than in another study 
which showed 4%.33 The administration of pamidronate 
is gradually being replaced by the increasing use of iban-
dronate and zoledronic acid.
Similar to previous studies, our study confirms that 
ibandronate is considered to be less potent from the point 
of view of BRONJ than zoledronic acid in the malignant 
indication.45 46 Zoledronic acid in NM indication causes 
BRONJ in 0.02%, while the result of the present study was 
0.22%.47 According to the results of other studies, BRONJ 
is present in approximately 0.7%–10% of zoledronic acid 
oncology patients.8 30 A lower percentage (1.2%) was 
found in the Hungarian BP population.
Intravenous BPs and aminoBPs have a stronger effect 
on developing BRONJ than oral and non-aminoBPs, 
according to the order of potency. There are fewer 
BRONJ cases in clodronate, risedronate and oral ibandro-
nate than alendronate, which is the result of the potency 
and the widespread use of alendronate.47 48 Alendronate 
shows a lower risk than intravenous BPs, while intrave-
nous ibandronate has a lower risk than pamidronate and 
zoledronic acid.8 49
There is a higher risk of BRONJ in a given BP drug 
group with a higher total dose in both main indications 
of BPs.8 31 46 50 In NM indications, the total length of the 
therapy has a stronger effect on the development of the 
side effects than the total dose.46 In this study, BRONJ 
patients were administered a significantly higher total 
dose of BP than no BRONJ patients in the oral clodronate, 
the pamidronate and the zoledronic acid groups. In iban-
dronate and alendronate patients, the total dose of BP in 
BRONJ patients was not significantly higher. In risedro-
nate patients, BRONJ patients had a lower total dose, but 
not significantly. In this case, we hypothesise the presence 
of other non-drug-dependent risk factors.
Table 5 Difference of proportion of BRONJ in the drug groups (on the basis of the results of table 3)
Drug groups 
CLO 
intravenous 
(95% CI) 
IBA oral 
(95% CI) 
IBA 
intravenous 
(95% CI) PAM (95% CI) ALE (95% CI) RIS (95% CI) ZOL (95% CI)
CLO oral
OR: 1.5
(0.1 to 24.8), 
p=0.78
OR: 0.5
(0.3 to 0.9), 
p=0.02
OR: 0.2
(0.1 to 0.4), 
p≤ 0.001
OR: 1.8
(0.9 to 3.7), 
p=0.11
OR: 0.2
(0.1 to 
0.3), p<0.001
OR: 0.1
(0.1 to 
0.2), p<0.001
OR: 1.0
(0.7 to 1.6), 
p=0.85
CLO 
intravenous*
OR: 0.3
(0.0 to 5.6), 
p=0.45
OR: 0.2
(0.0 to 2.7), 
p=0.20
OR: 1.2
(0.1 to 21.1), 
p=0.89
OR: 0.1
(0.0 to 2.0), 
p=0.14
OR: 0.1
(0.1 to 1.5), 
p=0.09
OR: 0.7
(0.0 to 11.2), 
p=0.79
IBA oral OR: 0.5
(0.3 to 0.8), 
p=0.002
OR: 3.5
(1.7 to 
7.1), p<0.001
OR: 0.4
(0.2 to 
0.6), p<0.001
OR: 0.3
(0.2 to 
0.4), p<0.001
OR: 2.1
(1.4 to 
3.1), p<0.001
IBA intravenous OR: 7.3
(3.7 to 
14.2), p<0.001
OR: 0.8
(0.5 to 1.1), 
p=0.12
OR: 0.6
(0.4 to 0.9), 
p=0.006
OR: 4.3
(3.0 to 
6.0), p<0.001
PAM OR: 0.1
(0.1 to 
0.2), p<0.001
OR: 0.1
(0.0 to 
0.1), p<0.001
OR: 0.6
(0.3 to 1.1), 
p=0.09
ALE OR: 0.7
(0.5 to 1.0), 
p=0.08
OR: 5.6
(4.4 to 
7.1), p<0.001
RIS OR: 7.6
(5.4 to 
10.6), p<0.001
Bold values are statistically significant. 
This table shows whether a drug has a stronger effect to develop BRONJ than the other one.
*In the case of intravenous CLO, 0.5 cases were added to each patients’ number in the equation to be able to count ORs.
ALE, alendronate; BRONJ, bisphosphonate-related osteonecrosis of the jaw; CLO, clodronate; IBA, ibandronate; PAM, pamidronate; 
RIS, risedronate; ZOL, zoledronic acid.
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Glucocorticoids increase the risk of BRONJ.50 51 The 
necrosis might occur earlier, it is more severe and reacts 
slower to the discarding of BP.52 In steroid BP patients, 
there is a significantly higher proportion of BRONJ 
patients than in the whole BP population. There is a 
higher risk of developing BRONJ when a higher dose of 
BP is administered to a patient with steroid comedication, 
and there are differences between the BP drugs. Alendro-
nate and risedronate BP dose is higher in the steroid No 
BRONJ group than in the steroid BRONJ group, and the 
zoledronic acid dose is lower, respectively. Alendronate 
and risedronate cumulative doses possibly have a weaker 
effect on BRONJ than the steroid comedication, and in 
the case of zoledronic acid, this effect is reversed.
limitations
The database which this research group could access did 
not include dose, prescription or medication data from 
the period before 2010. From the risk factors of BRONJ, 
cumulative doses and the length of the BP therapy were 
not analysable, and the exposure bias has not been 
considered in the absence of relevant data. This study was 
not registered to any databases of clinical trials.
Since there are no independent ICD and ICPM codes 
of this disease, a selection bias can occur, which is the 
limitation of the study. The applied screening method 
narrows the number of potential BRONJ patients.
The effect of the BP drugs were analysed without 
considering the effect of other risk factors and the inter-
dependence of the analysed risk factors. The single effect 
of the drugs, the main indication and the administration 
forms were compared. To analyse the combined effect 
of these factors, the application of a logistic regression 
model would be necessary.
COnClusIOns
These data are the first to have defined the incidence data 
of BRONJ in the Hungarian BP population according to 
the main indications of BPs and routes of administration. 
Our results show differences between BP drugs in their 
potential to cause BRONJ independently of their doses. 
Duality was typical in gender, main indication and also in 
the mode of administration of BPs. Male, oncology and 
intravenous BP patients were at a higher risk of devel-
oping BRONJ, but the significantly higher number of the 
opposite population of these groups resulted in a higher 
number of BRONJ in the groups of female patients, oste-
oporosis and oral BP patients. In the Hungarian BP popu-
lation, the risk increasing main factors of BRONJ were 
corticosteroid comedication and BPs with malignant indi-
cation. More studies are needed to find the interdepen-
dence of the analysed factors.
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